Apellis Pharmaceuticals
Buying intent
15 tracked signals | Top 14 topics are below | Marketing and Product are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Apellis Pharmaceuticals's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
4d ago
29d ago
18d ago
14d ago
4d ago
26d ago
10d ago
14d ago
29d ago
26d ago
4d ago
4d ago
10d ago
26d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Apellis Pharmaceuticals
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileApellis is now part of Biogen. Please follow along there for the latest news. In the coming weeks, this page will no longer be updated or monitored.
Top accounts researching Apellis Pharmaceuticals
names withheld on the public pageThese are companies whose own people brought up Apellis Pharmaceuticals unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
129,094 companies · 649,540 people are researching Artificial Intelligence
Apellis Pharmaceuticals's own team shows 2 signals on this topic. No one outside Apellis Pharmaceuticals has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Health Care6,524 cos · 23,607 people
- Social Proof641 cos · 1,645 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Marketing — 2 people; IT — 1 person; Product — 1 person
What's been said
public posts by Apellis Pharmaceuticals's teamNo public post naming Apellis Pharmaceuticals has surfaced in the past year, so this is what Apellis Pharmaceuticals's own team is posting about publicly — their topics, in their words.
Heading into next week's Marcus Evans PharmaMarketing Summit & look forward to discussing launches that don't follow the textbook. Smaller patient populations, complex HCP networks, competitive transitions, and the gap between what gets debated in conference rooms and what actually moves (the needle for) a brand. #PharmaMarketing #LaunchLeadership #RareDisease #MKTSummit
May 2026Excited for this new chapter with Biogen and looking forward to continuing to make an impact for patients alongside an incredible team!
May 2026Heading to San Antonio for the 51st Annual Oncology Nursing Society (ONS) Congress. Looking forward to the learning, the inspiration, and the conversations with oncology nurses driving care forward. If you'll be there, send me a DM here on LinkedIn to connect or stop by the Apellis booth #220 to say hi! #ONSCongress2026 #OncologyNursing #CareInMotion #Apellis #PatientCare
May 2026https://lnkd.in/g9V5e-pQ Optum Rx just announced a more transparent PBM pricing model built around flat monthly fees instead of pricing tied to rebates, drug list prices, or prescription volume. If the old payer story was built around rebate math, the new story may need to work harder: clear clinical value, patient affordability, and measurable outcomes - which it already is today in some specialties. Does this move us across the board though - closer to true outcomes-based contracting, or does the same negotiation just shift upstream to net price? Spencer Champagne David Bower #MarketAccess #PBM #Pharma #GTN #ValueBasedContracting #PharmaMarketing
May 2026I am proud to share my latest achievement with my LinkedIn network! I earned my ACRP-CP® certification in clinical research from the Association of Clinical Research Professionals (ACRP). ACRP-CP® formally recognizes clinical research professionals of all types, regardless of their roles or functional activities on the clinical study team.
May 2026Heading to Fort Lauderdale next week for the Marcus Evans PharmaMarketing Summit (May 18-19) at the Ritz-Carlton. Kellee King-Campbell Ike S. Clara LeBlanc https://lnkd.in/gmv4HRtM Joining a panel on "Redefining launch leadership: the mindset, models & metrics of modern brand success." Great lineup: Dan Joyce , Erric Byrd , Jay Shah, PharmD Imtiaz Hussain Three questions I'm bringing into the room: 1. How do you measure launch momentum when the patient pool is small and HCP behavior is the rate-limiter? 2. What's actually changed about brand leadership post-pandemic, and what's just been rebranded? 3. Where do mindset and metrics pull in opposite directions, and how do you call it? #PharmaMarketing #LaunchLeadership #RareDisease #BrandStrategy
May 2026The HBA Global Ascension Leadership Experience is this week in San Diego. If anyone in my network is attending, please reach out -- would love to meet in person! #HBAimpact #AscendWithHBA #HBALuminary Join the HBA in San Diego: https://lnkd.in/gr8i2_q2
Apr 2026